OGT2115 improves glucose profiles in STZ-induced diabetic mice
The intra-islet HS loss was prevented by treatment with, a heparanase
inhibitor, OGT2115 (Fig. 3A). The inhibitor was subcutaneously injected
into STZ-induced diabetic mice daily. The entire procedure was depicted
in Fig. 3B. After four weeks of administration, the random blood glucose
of STZ mice treated with 10 mg/kg OGT2115 was significantly reduced when
compared with vehicle-treated STZ mice (Fig. 3C). No alteration occurred
in body weight (Fig. 3D) or in food intake (Fig. 3E). An intraperitoneal
glucose tolerance test (IPGTT) showed that the OGT2115-treated STZ mice
exhibited improved glucose tolerance when compared with the
vehicle-treated group (Fig. 3F-G). During the IPGTT, the GSIS before and
30 min after glucose loading was increased in the STZ mice treated with
either 3 or 10 mg/kg OGT2115 when compared with the vehicle-treated STZ
mice (Fig. 3H).